- Home
- ALNY vs IR Comparison
ALNY vs IR Comparison
Compare ALNY & IR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- IR
- Stock Information
- Founded
- ALNY 2002
- IR 1859
- Country
- ALNY United States
- IR United States
- Employees
- ALNY N/A
- IR N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- IR Industrial Machinery/Components
- Sector
- ALNY Health Care
- IR Industrials
- Exchange
- ALNY Nasdaq
- IR Nasdaq
- Market Cap
- ALNY 35.0B
- IR 33.7B
- IPO Year
- ALNY 2004
- IR N/A
- Fundamental
- Price
- ALNY $250.59
- IR $83.71
- Analyst Decision
- ALNY Buy
- IR Buy
- Analyst Count
- ALNY 23
- IR 11
- Target Price
- ALNY $305.86
- IR $104.27
- AVG Volume (30 Days)
- ALNY 687.2K
- IR 2.6M
- Earning Date
- ALNY 02-13-2025
- IR 02-13-2025
- Dividend Yield
- ALNY N/A
- IR 0.10%
- EPS Growth
- ALNY N/A
- IR 8.42
- EPS
- ALNY N/A
- IR 2.06
- Revenue
- ALNY $2,248,243,000.00
- IR $7,235,000,000.00
- Revenue This Year
- ALNY $22.50
- IR $7.60
- Revenue Next Year
- ALNY $30.54
- IR $5.64
- P/E Ratio
- ALNY N/A
- IR $40.63
- Revenue Growth
- ALNY 22.97
- IR 5.22
- 52 Week Low
- ALNY $141.98
- IR $83.26
- 52 Week High
- ALNY $304.39
- IR $106.03
- Technical
- Relative Strength Index (RSI)
- ALNY 39.26
- IR 31.30
- Support Level
- ALNY $246.61
- IR $85.57
- Resistance Level
- ALNY $268.52
- IR $87.19
- Average True Range (ATR)
- ALNY 8.23
- IR 2.04
- MACD
- ALNY -3.61
- IR -0.74
- Stochastic Oscillator
- ALNY 12.20
- IR 4.11
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.2 billion in revenue in 2024.